Elutia agrees to sell SimpliDerm business to Cellution Biologics for up to $11 million
PUBT · 1d ago
Share
Listen to the news
- Elutia signed a definitive deal to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to USD 11 million.
- Terms include USD 8 million cash at closing, with up to USD 3 million tied to technology transfer and commercial milestones over 18 months.
- Closing is expected in the second half of 2026, subject to customary conditions.
- Divestiture shifts focus to NXT-41x, targeting a 2027 commercial launch in U.S. plastic and reconstructive surgery.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elutia Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607161605PRIMZONEFULLFEED9763644) on July 16, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending